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Background
The effectiveness of Allergy Immunotherapy is known to
subjectively improve quality of life. An opinion survey was
designed to elicit the perceived efficacy among immu-
notherapy patients with regards to the mitigation of symp-
toms of Allergic rhinitis, Allergic conjunctivitis, Atopic
dermatitis and improvement in Asthma control.
Methods
A 10 question voluntary anonymous survey on paper was
designed by a two-allergist team to assess the patient per-
ception of the improvement in quality of life on Allergy
Immunotherapy by the subcutaneous route. The measures
that were tested was perceived reduction as well as
improved control with regards to disease states such as
Allergic rhinitis, Asthma, Allergic conjunctivitis and Ato-
pic dermatitis. Distribution of the voluntary survey was
undertaken at 8 different sites. Responses were accepted
over a testing period of 14 working days from May 1 -
May 18, 2012.
Results
Of the 500 respondents from 8 different sites, 463 com-
pleted the complete survey. Only the data from completed
surveys underwent statistical analysis. 463 respondents
were in the age range of 5 years to 84 years and consisted
of 44% male and 56 % female. The data analyzed corre-
sponded to 1489 years (one thousand four hundred eighty
nine years) of subcutaneous injections. 82 % of the respon-
dents expressed the alleviation of symptoms of allergic
rhinitis, 43 % improvement in asthma control, 55 %
decrease in recurrent sinusitis, 56% decrease in allergic
conjunctivitis and 18 % decrease in atopic dermatitis. 97.6
% of respondents reported an improvement in quality of
life, 1.5 % reported no improvement and 0.9 % were
unsure.
Conclusions
Allergists caring for patients with atopic conditions can be
reassured that the perceived clinical efficacy of subcuta-
neous allergy immunotherapy is at an extremely high level
with regards to resolution of symptoms within the atopic
disease states that it is indicated for. Opinion surveys can
be a very helpful tool in assessing current patient level of
satisfaction to therapy regarding atopic disease states.
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